Cytokinetics wins Health Canada approval for MYQORZO to treat obstructive HCM

CYTK•2026-10-19

Health Canada approved Cytokinetics’ MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy classified as NYHA class II-III.

1. Canadian approval

Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy classified as NYHA class II-III.

Cytokinetics wins Health Canada approval for MYQORZO to treat obstructive HCM

1. Canadian approval

Related News

Eni completes Libya gas recovery project to curb CO₂ emissions

Nasdaq trade halt continues; reason not available at 7:55 am

Akeso opens global Phase II trial of ivonescimab in first-line kidney cancer

Freeport bets on chemical solution to reach copper leaching target

IRulya Therapeutics presents LAM-001 Phase 2a data in pulmonary hypertension